Drug Discovery– tag –
-
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 7)
Episode 7 | A Life-Course Prevention Playbook: Think in Life Events, Not Just Age—When to Seek Care, Screening Principles, and a Practical Summary Across this series, we placed breast, ovarian, and endometrial cancer risk on the same lif... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 6)
Episode 6 | Lifestyle and Women’s Cancer Risk: Weight, Activity, Alcohol, and Sleep—A Practical Plan to Lower Risk Without Chasing Perfection Hormonal milestones (menarche, pregnancy, menopause) shape women’s cancer risk over decades. Ho... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 5)
Episode 5 | Perimenopause and Menopausal Symptoms: Balancing Cancer Risk, Quality of Life, and the Role of HRT Menopause is often described as “estrogen going down,” but lived experience is usually about something else: fluctuation. Meno... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 4
Episode 4 | Endometrial Cancer, Hormone Balance, and Metabolic Health: The “Unopposed Estrogen” Intersection “My hormones feel off” is a common phrase—useful, but often too vague to drive action. “My hormones feel off” is a common phrase... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 3
Episode 3 | Ovarian Cancer: The “Silent Killer,” Reproductive Aging, and Why Detection Is Hard Ovarian cancer is sometimes called a “silent killer.” That phrase gained traction for two reasons: early symptoms are often not obvious, and t... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 2
Episode 2 | Breast Cancer Across Life Stages: Reading Risk Calmly with “Relative vs Absolute” Breast cancer is one of the most information-heavy topics in women’s health. Breast cancer is one of the most information-heavy topics in women... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 1
Episode 1 | A Life-Course Map of Female Hormones: From Puberty to Post-Menopause Women’s health topics are often discussed in separate “boxes”: symptoms (PMS, menstrual pain, menopause) on one side, and diseases (breast cancer, ovarian c... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Column B – A Practical ADC Strategy Checklist: Ten Questions for Pharma, Biotechs, Investors, and Advisors
In Column B, we translate the themes of this series into a practical checklist for people who must make decisions about ADCs in their daily work: In Column B, we translate the themes of this series into a practical checklist for people w... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Column A – How Enhertu Reshaped the ADC Landscape: A Case Study in Design, Clinical Strategy, and Business Impact
In Column A, we focus on Enhertu, the ADC that appears repeatedly throughout this series, and ask a simple but far-reaching question:Why did this part In Column A, we focus on Enhertu, the ADC that appears repeatedly throughout this seri... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 7 – Synthesis: Where We Stand in 2025 and How ADCs May Evolve Toward the 2030s
In Part 1, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we reviewed ADC design—a In Part 1, we explored why the ADC land grab is happening now and how ADCs fit into th... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 6 – Designing Oncology Portfolios Beyond ADCs: Positioning Bispecifics, Cell Therapies, and Radiopharmaceuticals
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we review In Part 1 of this series, we explored why the ADC land grab is happening now and how A... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 5 – The Rise of China and Asian ADC Players: How the Global Map Is Being Redrawn and Where Japan Can Stand
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we examin In Part 1 of this series, we explored why the ADC land grab is happening now and how A... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 4 – How to Read ADC Deals: M&A, Licensing, Co-development, and CDMO Agreements
In Part 1 of this series, we looked at why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we exami In Part 1 of this series, we looked at why the ADC land grab is happening now and how ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 3 – Patent Cliffs and ADCs: Why Big Pharma Wants ADCs as Growth Engines for the Next Decade
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit within the broader landscape of cancer therapies, highli In Part 1 of this series, we explored why the ADC land grab is happening now and how A... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 2 – ADC Structure and Generational Shift: What “Second- and Third-generation” ADCs Really Mean After Enhertu
In Part 1 of this series, we asked why the ADC land grab is happening now, and we positioned ADCs within the broader landscape of cancer therapies, di In Part 1 of this series, we asked why the ADC land grab is happening now, and we posi... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 1 – Why is There an ADC Land Grab Now? Introducing ADC’s Place in Cancer Therapy
Over the past few years, headlines about Antibody-Drug Conjugates (ADCs) have become hard to miss in oncology and biopharma news. Over the past few years, headlines about Antibody-Drug Conjugates (ADCs) have become hard to miss in oncolo... -
The Hidden Pitfall of AI Drug Discovery: The Quiet Wall of Reproducibility in Scientific Literature
Introduction: Past Knowledge Is Now the Starting Point of Future Drug Discovery AI-driven drug discovery has become an increasingly central part of modern pharmaceutical R&D. AI-driven drug discovery has become an increasingly centra... -
2026 Global Biotech & Pharma Outlook (Part 2) — Where Technological Progress Is Taking Shape —
Happy New Year. What you will learn AI and Life Sciences Enter a New PhaseThe Evolution of Drug Modalities and Design PhilosophyAdvancing In Vivo Approaches and Control TechnologiesRadiopharmaceuticals and Emerging Therapeutic PlatformsP... -
2026 Global Biotech & Pharma Outlook (Part 1) — Where Science and Innovation Are Heading —
Happy New Year. What you will learn The Current Global Environment for Biotech and PharmaInnovation Continues Beyond Market CyclesEvolving Relationships Between Capital, Policy, and ScienceWhy Global Collaboration Matters More Than EverW... -
Top 10 Global Biotech & Pharma News of 2025 (Ranked #5–#1) — Obesity, ADCs, China Licensing, and M&A Redrew the Map
The second half of 2025’s “top 10” is where the industry’s center of gravity moved. The second half of 2025’s “top 10” is where the industry’s center of gravity moved. The defining themes were clear: obesity drugs entering a second act (...
